Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

被引：0
作者：
Li, Jian
Xu, Ye
Zang, Aimin
Gao, Yunong
Gao, Quanli
Zhang, Yanqiao
Wang, Dong
Xu, Jianming
Yuan, Ying
Jiang, Haiping
Ying, Jieer
Shi, Chunmei
Deng, Yanhong
Wang, Jing
Liu, Tianshu
Huang, Yi
Xu, Yaling
Wang, Yidi
Fei, Cong
Shen, Lin
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Fudan Univ Shanghai, Canc Ctr, Shanghai, Peoples R China
[3] Hebei Univ, Affiliated Hosp, Hebei, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[5] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[6] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[8] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Zhejiang, Peoples R China
[9] Med Sch Zhejiang Univ, Affiliated Hosp 1, Zhejiang, Peoples R China
[10] Zhejiang Canc Hosp, Beijing, Peoples R China
[11] Fujian Med Univ, Union Hop, Fujian, Peoples R China
[12] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
[13] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[14] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[15] Hubei Canc Hosp, Wuhan, Hubei, Peoples R China
[16] BeiGene Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14556
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
    Overman, Michael J.
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Atasoy, Ajlan
    Zhao, Huanyu
    Lei, Ming
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [22] A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
    Kim, Jwa Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Cha, Yong Jun
    Ahn, Joong Bae
    Kim, Han Sang
    Lee, Keun-Wook
    Kim, Ji-Won
    Kim, Tae-You
    Chang, Won Jin
    Park, Joon Oh
    Kim, Jihun
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Yeul Hong
    Kim, Tae Won
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1135 - 1144
  • [23] MyTACTIC: Afficacy and safety of atezolizumab (atezo) plus chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR)
    Spigel, David R.
    Hussein, Maen A.
    Zuniga, Richard
    Mahadevan, Daruka
    Winn, Robert
    Darbonne, Walter C.
    Yoo, Bongin
    Kim, Young
    Whitehead, Zach
    Vanderwalde, Ari M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Pembrolizumab for patients with previously treated, mismatch repair-deficient microsatellite instability-high advanced colorectal carcinoma: phase 2 KEYNOTE-164 study
    Le Dung
    Thierry, Andre
    Won, Kim Tae
    Eric, Van Cutsem
    Dirk, Jaeger
    Ravit, Geva
    Hiroki, Hara
    You, Kim Tae
    Takayuki, Yoshino
    Matthew, Burge
    Hiroya, Taniguchi
    Elena, Elez
    Chloe, Atreya
    Johanna, Bendell
    Minori, Koshiji
    Wang Ruixue
    Peter, Kang S.
    Luis, Diaz
    ANNALS OF ONCOLOGY, 2016, 27 : 79 - 79
  • [25] Pembrolizumab (pembro) for previously treated, microsatellite instabilityehigh (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Le, D. T.
    Diaz, L.
    Kim, T. W.
    Van Cutsem, E.
    Geva, R.
    Jager, D.
    Hara, H.
    Burge, M.
    O'Neil, B.
    Kavan, P.
    Yoshino, T.
    Guimbaud, R.
    Taniguchi, H.
    Elez, E.
    Al-Batran, S-E.
    Boland, P.
    Cui, Y.
    Leconte, P.
    Marinello, P.
    Andre, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S550 - S550
  • [26] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
    Overman, Michael J.
    Lenz, Heinz-Josef
    Andre, Thierry
    Aglietta, Massimo
    Wong, Mark Ka
    Luppi, Gabriele
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hendlisz, Alain
    Cardin, Dana Backlund
    Morse, Michael
    Neyns, Bart
    Hill, Andrew Graham
    Limon, M. Luisa
    Garcia-Alfonso, Pilar
    Krishnamurthy, Anuradha
    Chen, Franklin
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.
    Andre, Thierry
    Elez, Elena
    Lenz, Heinz-Josef
    Jensen, Lars Henrik
    Touchefeu, Yann
    Van Cutsem, Eric
    Garcia-Carbonero, Rocio
    Tougeron, David
    Mendez, Guillermo
    Schenker, Michael
    de la Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Aubin, Francine
    Cela, Elvis
    Chen, Tian
    Lei, Ming
    Jin, Lixian
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA143 - LBA143
  • [28] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [29] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Andre, T.
    Van Cutsem, E.
    Elez, E.
    Bennouna, J.
    de la Fouchardiere, C.
    Yoshino, T.
    Jensen, L.
    Mendez, G.
    Li, J.
    Goekkurt, E.
    Abdullaev, S.
    Chen, T.
    Lei, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
  • [30] FREQUENCY OF AND TESTING PATTERNS FOR MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS IN A US COMMUNITY ONCOLOGY SETTING
    Chase, M.
    Vasudevan, A.
    Amonkar, M.
    Myer, N.
    Wang, T.
    Prabhu, V
    Turzhitsky, V
    Spira, A.
    VALUE IN HEALTH, 2022, 25 (07) : S452 - S452
12345